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ABSTRACT
OBJECTIVE
To examine the effect of optimising drug treatment 
on drug related hospital admissions in older adults 
with multimorbidity and polypharmacy admitted to 
hospital.
DESIGN
Cluster randomised controlled trial.
SETTING
110 clusters of inpatient wards within university 
based hospitals in four European countries 
(Switzerland, Netherlands, Belgium, and Republic of 
Ireland) defined by attending hospital doctors.
PARTICIPANTS
2008 older adults (≥70 years) with multimorbidity (≥3 
chronic conditions) and polypharmacy (≥5 drugs used 
long term).
INTERVENTION
Clinical staff clusters were randomised to usual 
care or a structured pharmacotherapy optimisation 
intervention performed at the individual level jointly 
by a doctor and a pharmacist, with the support of 
a clinical decision software system deploying the 
screening tool of older person’s prescriptions and 
screening tool to alert to the right treatment (STOPP/
START) criteria to identify potentially inappropriate 
prescribing.
MAIN OUTCOME MEASURE
Primary outcome was first drug related hospital 
admission within 12 months.
RESULTS
2008 older adults (median nine drugs) were 
randomised and enrolled in 54 intervention clusters 
(963 participants) and 56 control clusters (1045 
participants) receiving usual care. In the intervention 
arm, 86.1% of participants (n=789) had inappropriate 
prescribing, with a mean of 2.75 (SD 2.24) STOPP/
START recommendations for each participant. 62.2% 
(n=491) had ≥1 recommendation successfully 
implemented at two months, predominantly 
discontinuation of potentially inappropriate drugs. 
In the intervention group, 211 participants (21.9%) 
experienced a first drug related hospital admission 
compared with 234 (22.4%) in the control group. In 
the intention-to-treat analysis censored for death as 
competing event (n=375, 18.7%), the hazard ratio for 
first drug related hospital admission was 0.95 (95% 
confidence interval 0.77 to 1.17). In the per protocol 
analysis, the hazard ratio for a drug related hospital 
admission was 0.91 (0.69 to 1.19). The hazard ratio 
for first fall was 0.96 (0.79 to 1.15; 237 v 263 first 
falls) and for death was 0.90 (0.71 to 1.13; 172 v 203 
deaths).
CONCLUSIONS
Inappropriate prescribing was common in older adults 
with multimorbidity and polypharmacy admitted to 
hospital and was reduced through an intervention 
to optimise pharmacotherapy, but without effect on 
drug related hospital admissions. Additional efforts 
are needed to identify pharmacotherapy optimisation 
interventions that reduce inappropriate prescribing 
and improve patient outcomes.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Inappropriate drug prescribing is highly prevalent in older people with 
multimorbidity and polypharmacy and has been associated with negative health 
outcomes, including excess drug related hospital admissions
Interventions aimed at optimisation of pharmacotherapy might improve 
prescribing quality and lower risk of adverse drug reactions
The effect of pharmacotherapy optimisation aimed at reduced inappropriate 
prescribing on clinical outcomes is uncertain, including on drug related hospital 
admissions in older adults with multimorbidity
WHAT THIS STUDY ADDS
A structured pharmacotherapy optimisation intervention, performed jointly by a 
doctor and a pharmacist with the support of a clinical decision software system, 
reduced inappropriate prescribing
The intervention did not, however, significantly affect drug related hospital 
admissions
The intervention caused no detriment to patient outcomes
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Introduction
Multimorbidity, defined as two or more chronic medical 
conditions, increases with age, with an estimated 
prevalence of 70% or more in older populations aged 
65 years and older, and is accompanied by increased 
mortality, healthcare utilisation, hospital admissions, 
and prescription rates of long term drugs.1-4 
Multimorbidity commonly results in polypharmacy, 
often defined as the long term use of five or more 
prescribed drugs daily.5 Although polypharmacy 
might be indicated and beneficial in many people with 
multimorbidity, the risk of inappropriate prescribing is 
also increased.6 7 Inappropriate prescribing might take 
the form of drug overuse (drug prescribing without an 
evidence based indication), drug underuse (omission 
of drug prescribing despite an evidence based 
indication), or drug misuse (such as inappropriate 
combinations with risk for drug-drug interactions, and 
inappropriate dosing).8-11 Inappropriate prescribing 
is highly prevalent among older people, varying from 
30% to 60%,10 12 and could lead to important adverse 
outcomes.6 Studies have reported increased risks of 
drug-drug interactions and adverse drug reactions,13 
drug related hospital admissions, falls, mortality, and 
decreased quality of life arising from inappropriate 
prescribing in the context of polypharmacy.6 7 14 15 As 
much as 30% of hospital admissions in older people 
are related to drugs, half of which are potentially 
preventable.15-18
A wide variety of interventions have been 
designed to optimise pharmacotherapy in people 
with polypharmacy, with the aim of improving drug 
appropriateness and lowering the risk of adverse drug 
reactions.7 Most of these structured interventions 
consist of multifaceted strategies delivered by 
pharmacists,7 but more recently, software systems 
have been developed to support pharmacotherapy 
optimisation.19 20 Although most computerised 
decision support systems focus on a single aspect, such 
as detecting drug-drug or drug-disease interactions, or 
potentially inappropriate drugs,21 the systematic tool 
to reduce inappropriate prescribing (STRIP) facilitated 
by the web based STRIP assistant (STRIPA) can 
perform multiple tasks intrinsic to pharmacotherapy 
optimisation simultaneously. STRIP combines the 
screening tool of older person’s prescriptions and 
screening tool to alert to the right treatment (STOPP/
START) criteria22 with a more global evaluation of drug 
appropriateness and shared decision making with 
the patient.23 It remains uncertain, however, whether 
these structured pharmacotherapy optimisation 
interventions result in improved clinical outcomes. A 
Cochrane systematic review of interventions designed 
to improve the appropriate use of polypharmacy in 
older people found few studies investigating important 
clinical outcomes, such as hospital admissions 
or quality of life, with inconsistent results. While 
some prospective non-randomised studies have 
indicated a reduction in hospital admissions with 
multifaceted interventions of drug care,24 25 and 
two small single centre randomised controlled trials 
showed a reduction in hospital admissions,16  26 
other randomised controlled trials failed to show 
any relevant benefit on clinical outcomes.7 27 The 
certainty of the evidence was, however, deemed to 
be very low because of limitations in study design, 
including risk of bias (eg, contamination bias due to 
non-cluster randomisation, outcome assessment bias 
due to non-adjudicated outcomes), lack of statistical 
power (small sample size), short follow-up, or single 
site studies.7 Adequately powered high quality trials 
are therefore needed to assess the potential clinical 
benefit of pharmacotherapy optimisation; if effective, 
optimisation of pharmacotherapy could lead to major 
improvements in the care of the growing population of 
older adults with multimorbidity and polypharmacy. 
Improving drug appropriateness is particularly 
important among inpatients, given that drug related 
adverse events and inappropriate prescribing are risk 
factors for hospital admission.16
To overcome the limitations of previous 
pharmacotherapy optimisation studies,7 we conducted 
a large scale multicentre cluster randomised controlled 
trial (Optimizing Therapy to Prevent Avoidable Hospital 
Admissions in Multimorbid Older Patients, OPERAM) 
to assess the effect of a multidisciplinary optimisation 
of pharmacotherapy, supported by a software based 
clinical decision support tool on adjudicated drug 
related hospital admissions and other clinical 
outcomes in older adults with multimorbidity and 
polypharmacy, compared with usual care.
Methods
Trial design
The rationale and design of the OPERAM trial have been 
published previously.28 We conducted a multicentre, 
partially blinded cluster randomised controlled 
trial among older adults with multimorbidity and 
polypharmacy who were admitted to hospital. The 
trial, conducted in four university based hospitals 
located in four European countries (Bern, Switzerland; 
Utrecht, Netherlands; Louvain, Belgium; Cork, 
Republic of Ireland), assessed the effects of a structured 
pharmacotherapy optimisation intervention on 
drug related hospital admission. Written informed 
consent was obtained from the patients or their legal 
representatives before enrolment.
Participants
Adults aged 70 years or more with multimorbidity 
(≥3 chronic conditions defined by international 
classification of diseases, 10th revision, codes with 
an estimated duration of ≥6 months or based on a 
clinical decision) and polypharmacy (≥5 daily drugs 
used for >30 days before eligibility assessment) 
who were admitted to a participating hospital ward 
were eligible for inclusion if their expected minimal 
length of stay within the cluster was sufficient for 
the intervention to be applied. Patients admitted to 
medical or surgical wards, as well as those admitted 
for elective or emergency reasons, were included if 
they were ultimately admitted to hospital. To increase 
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external validity,29 we applied few exclusion criteria: 
planned transfer to palliative care within 24 hours 
after admission, report of any structured drug review 
by a clinician within two months before enrolment, 
and the inability to provide written informed consent 
or to obtain written informed consent from a proxy.
Randomisation and blinding
The clusters were defined at the level of attending 
hospital doctors. No specific eligibility criteria were 
defined for doctors other than sufficient enrolment 
potential. Doctors were sequentially enrolled over 21 
months and allocated in a 1:1 ratio to the intervention 
or control arms. To ensure intervention safety and to 
enable shared decision making with the participants, 
the trial was partially blinded. The intervention team 
consisted of a doctor and a pharmacist; neither was 
blinded to enable direct interactions with both the 
attending hospital doctors and the participants. 
The participants, hospital doctors, and general 
practitioners were partially blinded and received 
only general information on the trial without specific 
details about the intervention. Each cluster defining 
hospital doctor was instructed to keep trial arm 
allocations confidential and not to share information 
with colleagues. In addition, cluster defining hospital 
doctors worked on separate hospital units and were 
autonomous in their treatment decisions, further 
minimising contamination between clusters. To 
limit selection bias,30 the recruitment team, the 
teams conducting follow-up telephone calls, and the 
adjudication teams consisting of pharmacists and 
doctors were fully blinded.
Trial procedures
The trial protocol describing the intervention used 
in this study has been previously published.31 The 
intervention was performed at individual patient level 
and consisted of a structured drug review using STRIP, 
a process developed to support pharmacotherapy 
optimisation in older patients. STRIP combines 
the STOPP/START criteria22 to detect drug overuse 
and underuse with implicit drug appropriateness 
assessment methods, such as structured questions 
on drug history, treatment adherence, adverse drug 
reactions, and shared decision making with the 
patient on proposed changes to medication.23 A 
detailed description of the intervention is available 
in the Methods appendix of the supplementary file. 
This process was supported by the web based STRIPA 
(see Methods appendix in the supplementary file), 
a decision support system that takes into account 
clinically relevant interactions, dose adjustment 
according to renal function, and predictable adverse 
drug effects.23 32 33
Preadmission drug use was assessed with the 
Structured History taking of Medication (SHiM) 
questionnaire34 (see Methods appendix in the 
supplementary file) and entered into STRIPA along with 
the patient’s current diagnoses and relevant laboratory 
values. A trained research doctor and pharmacist 
jointly performed the STRIP drug review and generated 
patient specific prescribing recommendations based on 
STOPP/START criteria, with possible adaptations after 
discussion with the attending hospital doctor and the 
patient to take patient preferences into account. After 
considering additional in-hospital clinical information 
(eg, new diagnoses, history of adverse drug reactions), 
a final report was sent to the patient’s GP with further 
recommendations that could not be implemented 
during the index hospital admission.
The control group received usual care that could 
include unstructured drug review by the attending 
hospital doctors, which was not specifically 
encouraged or discussed. Usual care was performed 
according to site specific standards of care that did not 
include application of STOPP/START criteria or STRIP. 
To mimic the intervention for blinding purposes of the 
participants and team members, the intervention team 
administered a sham intervention to all participants 
through completion of the Morisky medication 
adherence measure questionnaire (MMAS-8).35-37
Blinded team members collected follow-up and 
outcome data through telephone interviews with the 
participants or their proxies at 2, 6, and 12 months 
post-randomisation. When a hospital admission (at the 
index hospital or any other hospital) was identified, 
a second unblinded team gathered data on hospital 
admission and concealed all information identifying 
the intervention allocation before sending it to the 
adjudication team.
Outcomes
The primary outcome was the first confirmed drug 
related hospital admission after discharge following 
the index hospital admission within 12 months of 
enrolment. An independent blinded adjudication 
committee at each trial site, consisting of doctors 
and pharmacists, consecutively adjudicated all 
hospital admissions (both medical and surgical) for 
drug relatedness according to a previously published 
standardised adjudication guideline.38 Briefly, 
potential adverse drug events were identified with 
the aid of triggers (linked to both causative drugs 
and potential causes for underuse) and screening 
questions, based on review of medical records and 
drug lists. If goals of care or patient preferences were 
documented in the medical record, the adjudication 
team also took these into account. The blinded 
adjudication committee then adjudicated these 
confirmed adverse drug events for relatedness to 
the hospital admission. When adverse drug events 
were judged to be the main or a major contributory 
reason, the admission was identified as a drug related 
hospital admission. Hospital admissions leading to 
death were also adjudicated for drug related hospital 
admission, but not those for diagnostic or elective 
procedures for pre-existing conditions, or outpatient 
or emergency department visits, as the documentation 
for such visits is often too incomplete for adjudication 
of drug relatedness. During trial conduct, but before 
enrolment ended and without data being looked at, 
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non-substantial clarifications of the primary outcome 
definition were introduced: clarification that the effect 
measure was a hazard ratio, and shorter description of 
what constitutes a hospital admission in ClinicalTrials.
gov.
Secondary outcomes within 12 months of enrolment 
included all cause mortality, cancer mortality 
(negative control outcome to assess selection bias and 
blinding,39 as it was not expected to be influenced by 
the intervention), incident falls, and quality of life 
(visual analogueue scale of the European quality of 
life-5 dimensions (EQ-5D) questionnaire40). Other 
outcomes were selected according to a core outcome 
set for trials of drug review in older people with 
multimorbidity and polypharmacy41 and included pain 
or discomfort score (EQ-5D questionnaire), number of 
long term prescription drugs, activities of daily living 
(Barthel index of activities of daily living42), and drug 
compliance (MMAS-835), with month 12 as the main 
outcome month.
Secondary outcomes within two months after 
enrolment included the presence of drug overuse and 
misuse (based on STOPP criteria22), drug underuse 
(defined by START criteria22), and clinically significant 
drug-drug interactions43 (see Methods appendix 
in supplementary file). As a process measure for 
intervention participants, we calculated the number 
of STOPP/START recommendations made to attending 
hospital doctors and the number of implemented 
recommendations at two months.
We also added two post hoc outcomes: first 
confirmed preventable drug related hospital 
admission, considering admissions to be preventable 
when deemed potentially related to inappropriate 
prescribing (drug overuse, underuse, or misuse as 
evaluated by the adjudication committee), and first 
drug related hospital admission in a subpopulation, 
restricting the intervention group to participants with 
one STOPP recommendation or more implemented 
after two months.
Statistical analysis
We based the sample size estimation of 80 clusters with 
2000 patients for the primary outcome on an estimated 
one year event rate of one drug related hospital 
admission or more in 20% of the control group,17 44 
one year mortality of 20%,45 assumed one year drop-
out rate of 6%, 80% power to detect a 30% relative 
risk reduction in the intervention group at a two sided 
type 1 error level of 0.05, an assumed intracluster 
correlation coefficient of 0.02,46 and variable cluster 
sizes from 12 to 38 (mean 25) participants.28 47 The 
30% relative risk reduction was based on assessment 
of the effect that we did not want to miss.48
The primary analysis was performed according 
to intention to treat, including all clusters and 
participants in the allocated groups. We analysed the 
between group difference for the primary outcome 
using a mixed effects Cox proportional hazards 
model with a fixed effect for the intervention group 
and random effects for site and attending hospital 
doctor.49  50 Participants were censored at death to 
calculate cause specific hazard ratios. An additional 
analysis used extensions of the Fine-Gray proportional 
hazards model that accounts for clustering in 
competing risk settings, treating death as the 
competing event to calculate subdistribution hazard 
ratios.49 Statistics were reported with their respective 
95% confidence intervals and P values. We similarly 
analysed all cause deaths, cancer related deaths, all 
cause hospital admissions, falls, and preventable drug 
related hospital admissions.
We used mixed effects logistic regression to analyse 
between group differences for in-hospital death, drug-
drug interaction, and drug overuse, underuse, or 
misuse with a fixed effect for the intervention group 
and random effects for site and attending hospital 
doctor. Between group differences for continuous 
outcomes were analysed using mixed effects linear 
regression models with fixed and random effects, and 
adjustment for baseline values.
Prespecified subgroup analyses considered sex, 
age (<80 years v ≥80 years), home accommodation 
(independently living v non-independently living), 
presence of dementia, number of drugs used daily 
(<10 v 10), number of comorbidities (<median v 
≥median), cluster specialty (medical v surgical), and 
trial site.
In prespecified sensitivity analyses we adjusted 
for baseline characteristics and investigated time 
variation of the intervention effect.51 A post hoc added 
sensitivity analysis only considered data collected in 
interviews conducted within protocol specified time 
windows.
Per protocol analyses were performed for time-
to-first-event outcomes, omitting attending hospital 
doctors and patients with predefined protocol 
deviations (allocated intervention not received, cluster 
size <5 patients, violated inclusion or exclusion criteria) 
and intervention group patients for whom none of the 
STOPP/START recommendations were implemented at 
two months.52
The supplementary file describes the statistical 
analysis plan in detail. All analyses were performed 
using R version 3.6.0 software.53
The trial results are reported in line with the 
Consolidated Standards of Reporting Trials extension 
for cluster trials.54
Patient and public involvement
As part of the OPERAM project, patients and family 
care givers, healthcare professionals, and experts 
were involved in interviews and an international 
Delphi survey to develop an international core 
outcome set for clinical trials of drug review in older 
people with multimorbidity and polypharmacy41; 
this core outcome set was added to the OPERAM trial 
outcomes. The contribution of patients and family 
care givers was pivotal to the choice of the core 
outcome set, particularly for the final inclusion of 
“pain relief” as one of the seven outcomes retained 
in this set.41
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Results
Between 1 December 2016 and 31 October 2018, 
2008 older adults (median age 79 years (interquartile 
range 74-84 years); 898 (44.7%) women) provided 
consent and were enrolled in 54 intervention 
clusters (963 participants) and 56 control clusters 
(1045 participants) receiving usual care (fig 1 and 
supplementary eFig 1). During follow-up, 10 (0.5%) 
participants were lost to follow-up, 118 (5.9%) 
withdrew from the trial, and 385 (19.2%) died (375 
within 365 days).
Cluster size, specialty type, and interval between 
first and final patient recruitment were similar between 
the groups (table 1). Patient characteristics, number 
of comorbidities, number of daily drugs, and length 
of stay during index hospital admission were also 
similar between the groups. At baseline the patients 
used a median of nine drugs and had a median of 11 
comorbidities. The types of drugs used were similar 
between the groups (supplementary eTable 1). The 
average time spent on the full intervention by each 
participants, including data recording and discussion 
with the participant, was 97 minutes.
Of 916 patients who received the intervention 
(fig 1), 789 (86.1%) had at least one STOPP/START 
recommendation provided to their attending 
hospital doctor, with a mean of 2.75 (SD 2.24) 
recommendations for each participant (table 2). In 
total, 2331 recommendations were made, of which 
1524 (65.4%) were STOPP recommendations and 
807 (34.6%) were START recommendations. Implicit 
STOPP criteria, such as STOPP A1 and STOPP A3, were 
common (table 3). After two months, at least one of 
these recommendations was successfully implemented 
in 491 participants (62.2% of all participants in the 
intervention group with ≥1 recommendation), with a 
mean of 1.16 (SD 1.48) implemented recommendations 
for each participant, primarily discontinuation of 
potentially inappropriate drugs (table 2).
Primary outcome
A first confirmed drug related hospital admission 
occurred in 211 (21.9%) participants in the intervention 
group and 234 (22.4%) in the control group (table 4 
and supplementary eFigure 2). Supplementary eTable 
2 lists the drug classes implicated in drug related 
hospital admissions. In the intention-to-treat analysis, 
applying censoring for death at time of death, the 
hazard ratio for drug related hospital admission was 
0.95 (95% confidence interval 0.77 to 1.17). In the 
per protocol analysis, the hazard ratio was 0.91 (0.69 
to 1.19, supplementary eTable 3 and eFigure 3), with 
similar results in sensitivity analyses of competing 
risk of death, adjusting for baseline characteristics, 
and assessing varying intervention effect across time 
(supplementary eTables 4-6). In post hoc analyses, 
the hazard ratio for a first preventable drug related 
hospital admission (41% of first confirmed drug 
related hospital admissions) was 0.89 (0.63 to 1.25), 
and the hazard ratio was 0.88 (0.65 to 1.19) for first 
drug related hospital admission in participants with at 
least one STOPP recommendation implemented after 
two months (n=398 in the intervention group, n=875 
in the control group still in the trial); this analysis of a 
subset of intervention patients is exploratory as it might 
be biased from unequal distribution of confounding 
factors. The intervention effect on drug related hospital 
admissions did not differ in prespecified subgroup 
analyses, except for trial site (Louvain, Belgium: 
hazard ratio 0.50, 95% confidence interval 0.30 to 
0.85, P=0.05 for interaction) and dementia diagnosis 
(P=0.04 for interaction) (supplementary eFigure 4).
Secondary outcomes
The event rates for falls were 0.49 and 0.59 per 
person year in the intervention and control groups, 
respectively, with a hazard ratio for first fall of 0.96 
(0.79 to 1.15) among intervention participants. 
The hazard ratio for death was 0.90 (0.71 to 1.13; 
table 4 and supplementary eFigure 5). Drug related 
outcomes, pain, activities of daily living status, and 
drug adherence did not differ significantly between 
the groups, except for quality of life at 12 months, 
which was better in the intervention group (between 
group adjusted mean difference 2.29, 95% confidence 
interval 0.31 to 4.26, table 5). Results were similar in 
per protocol analyses, as well as in sensitivity analyses 
of competing risk of death, adjusting for baseline 
characteristics, time varying intervention effect, and 
exclusion of interviews outside prespecified time 
windows (supplementary eTables 3-7). Subgroup 
analyses of all cause mortality showed potential 
benefits for men, patients aged 80 years and older, and 
those randomised in Louvain (P=0.004, P=0.01, and 
P=0.02 for interaction, respectively; supplementary 
eFigure 6). The intracluster correlation coefficients 
for the main outcomes were in the expected range 
(supplementary eTable 8).
Discussion
In this cluster randomised controlled trial evaluating 
the effect of a structured pharmacotherapy 
optimisation intervention in older patients with 
multimorbidity and polypharmacy, five out of six 
participants experienced inappropriate prescribing. 
On average, 2.75 STOPP/START recommendations 
were provided for each participant in the intervention 
group, and 62% of participants in the intervention 
group had at least one recommendation implemented 
at two months, mostly discontinuation of drug overuse. 
Reduction of potentially inappropriate prescribing led 
to no detriment to patient outcomes, but drug related 
hospital admissions were not significantly reduced 
during a 12 month follow-up period, compared 
with usual care, despite providing evidence based 
recommendations to hospital doctors, patients, and 
their GPs.
Comparison with other evidence
Few randomised controlled trials have assessed 
the impact of reducing inappropriate prescribing 
on clinical outcomes. A previous Cochrane review 
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Assessed for eligibility
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Allocated to intervention group (in 54 clusters)
Received allocated intervention*916
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Intention to treat analysis
963
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Fig 1 | Flow of participants through study. *Reasons for not receiving intervention in intervention group: discharge or transfer from hospital before 
intervention could be applied (n=25), patient died before intervention could be applied (n=7), withdrawal from study before intervention could be 
applied (n=6), and other or unknown (n=9). †Time windows for follow-up interviews: ±14 days at two months; ±30 days at six months; ±30 days at 
12 months. ‡Participants or their proxies could not be reached for interview but excludes reasons for study discontinuation. §Reasons listed for 
exclusion in the per protocol analysis are not mutually exclusive
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of pharmacotherapy optimisation interventions in 
older people identified nine randomised controlled 
trials reporting hospital admissions as outcomes, 
seven of which found no significant difference 
between intervention and control groups.7 However, 
the primary endpoint of these studies was often 
non-clinical and measurement methods varied 
considerably across these studies. The review judged 
the risk of bias for this outcome as very high, owing 
to risk of contamination between groups, insufficient 
blinding, selective reporting, lack of adjudication 
of clinical outcomes, short follow-up, or small 
sample size. In addition, only four of these trials 
were conducted in patients admitted to hospital. 
Hospital admissions and emergency department 
visits were reduced in one small trial (n=110), the 
setting of which differed substantially from ours 
in that it included only patients undergoing first 
Table 1 | Baseline characteristics of clusters and patients. Values are numbers (percentages) unless stated otherwise
Characteristics Control Intervention
Clusters
No of clusters 56 54
Median (interquartile range) cluster size 16.0 (11.8-25.2) 16.5 (10.0-23.8)
Cluster specialty type:
 Medical 42 (75) 43 (80)
 Surgical 14 (25) 11 (20)
Median (interquartile range) time between first and last recruitment (weeks) 24.6 (15.2-37.3) 23.9 (11-35.9)
Participants
No of participants 1045 963
Cluster specialty type*:
 Medical 825 (78.9) 764 (79.3)
 Surgical 220 (21.1) 199 (20.7)
Median (interquartile range) age (years) 79 (74-84) 79 (74-84)
Age group (years):
<80 557 (53) 521 (54)
≥80 488 (47) 442 (46)
Women 453 (43) 445 (46)
Trial site:
 Bern, Switzerland 376 (36) 446 (46)
 Cork, Republic of Ireland 208 (20) 138 (14)
 Louvain, Belgium 238 (23) 150 (16)
 Utrecht, Netherlands 223 (21) 229 (24)
Median (interquartile range) No of comorbidities 10 (8-15) 11 (8-16)
 Missing data 1 (0.1) 2 (0.2)
Median (interquartile range) No of drugs 9 (7-12) 10 (7-13)
 Missing data 1 (0.1) 2 (0.2)
Non-independent living† 216 (21) 168 (17)
Dementia 49 (5) 51 (5)
Any fall during past year 405 (39) 364 (38)
 Median (interquartile range) No of falls during past year 0 (0-1) 0 (0-1)
 Missing data 7 (0.7) 12 (1.2)
Any hospital admission during past year 533 (51) 486 (51)
 Median (interquartile range) No of hospital admissions during past year 1 (0-1) 1 (0-1)
 Missing data 7 (0.7) 5 (0.5)
Median (interquartile range) body mass index 26.5 (23.7-30.1) 26 (23.2-29.6)
 Missing data 88 (8.4) 75 (7.8)
Current smoker 81 (8) 77 (8)
Median (interquartile range) quality of life‡ 60 (45-72) 60 (50-73)
 Missing data 56 (6.5) 36 (3.7)
Median (interquartile range) pain or discomfort score (EQ-5D)§ 1 (0-2.00) 1 (0-2.00)
 Missing data 13 (1.2) 7 (0.7)
Median (interquartile range) activities of daily living¶ 90 (80-100) 95 (75-100)
 Missing data 29 (2.8) 16 (1.7)
Median (interquartile range) drug compliance** 7 (6-7) 7 (6-7)
 Missing data 47 (4.5) 52 (5.4)
Median (interquartile range) length of stay during index hospital admission (days) 9 (6-14) 8 (6-13)
 Missing data 12 (1.1) 16 (1.7)
Numbers (percentages) are based on all data (missing and not missing).
Use of Morisky medication adherence measure questionnaire is protected by US copyright laws. Permission for use is required. A license agreement is 
available from Donald E Morisky, ScD, ScM, MSPH, Professor, Department of Community Health Sciences, UCLA Fielding School of Public Health, 650 
Charles E Young Drive South, Los Angeles, CA 90095-1772, USA (dmorisky@ucla.edu).
*Randomisation unit: attending hospital doctor responsible for a ward.
†Resident of nursing home (at least three months in six months before index admission) or housebound.
‡Measured by visual analogueue scale, second part of European quality of life-5 dimensions questionnaire (EQ-VAS). Values range from 0 to 100. Higher 
values indicate higher quality of life.
§Measured using five dimensions version of EQ-VAS. Values ranged from 0 to 4. Higher values indicate higher level of pain or discomfort.
¶Measured using Barthel index. Values range from 0 to 100. Higher values indicate higher functional independence.
**Measured using medication adherence questionnaire (MMAS-8). Values ranged from 0 to 8. Higher scores indicate higher levels of adherence.
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time transfer to a long term care facility, was single 
blinded (primary outcome assessors blinded), and the 
intervention was performed by a pharmacist transition 
coordinator.26 Another randomised controlled trial of 
368 participants aged 80 years and older admitted to 
hospital (with and without polypharmacy) compared 
drug review performed by ward based pharmacists 
with usual care and found an 80% (95% confidence 
interval 59% to 90%) subsequent reduction in 
drug related readmissions to hospital.16 Outcomes 
were not, however, independently adjudicated, and 
generalisability of the results was limited owing to 
the single centre design. Other randomised controlled 
trials had additional limitations, such as short follow-
up, single centre design, and insufficient power to 
identify a difference in hospital admissions.7
More recently, the SENATOR (Software ENgine for 
the Assessment and optimization of drug and non-
drug Therapy in Older peRsons) randomised controlled 
trial of 1537 older people with multimorbidity and 
polypharmacy admitted to hospital compared software 
guided advice on medication optimisation provided 
to attending doctors with standard care and found no 
between group difference for adverse drug reactions or 
for the secondary endpoints of readmission or death.19 
Implementation of drug advice was low (about 15%), 
blinding was limited, and contamination risk was 
not completely eliminated owing to individual level 
Table 2 | Systematic tool to reduce inappropriate prescribing (STRIP) recommendations to optimise prescribing in older 
adults (n=916)
Recommendations Estimate Minimum-maximum
Recommendations by STRIP method
Mean (SD) No of recommendations per patient 2.75 (2.24) 0-19
No (%) of participants with at least one recommendation 789 (86.1)
Mean (SD) No of STOPP recommendations per participant 1.79 (1.89) 0-18
No (%) of participants with at least one STOPP recommendation 665 (72.6)
Mean (SD) No of START recommendations per participant 0.95 (1.17) 0-7
No (%) of participants with at least one START recommendation 497 (54.3)
Recommendations implemented at 2 months*
Mean (SD) No of implemented recommendations per participant 1.16 (1.48) 0-12
 Missing data: 57 (6.2%)
No (%) of participants with at least one implemented recommendation 491 (62.2)†
Mean (SD) No of implemented STOPP recommendations per participant 0.93 (1.35) 0-12
 Missing data: 47 (5.1%)
Mean (SD) No of implemented START recommendations per participant 0.22 (0.54) 0-4
 Missing data; 38 (4.1%)
STRIP=systematic tool to reduce inappropriate prescribing; STOPP=screening tool of older people’s prescriptions; START=screening tool to alert to right 
treatment.
*In case of death, loss to follow-up, or withdrawal before two months, information on the implementation of the recommendation was judged as missing.
†Denominator is 789 patients with at least one recommendation, excluding patients without recommendations.
Table 3 | Ten most common identified screening tool of older person’s prescriptions and screening tool to alert to the right treatment (STOPP/START) 
criteria of 2331 recommendations made, and implementation at two months
STOPP/START Description
No (%)
Count in intervention 
group Implemented* Not implemented
STOPP
STOPP A1† Any drug prescribed without an evidence based clinical indication 828 (35.5) 428 (51.7) 400 (48.3)
STOPP A3 Any duplicate drug class prescription 147 (6.3) 95 (64.6) 52 (35.4)
STOPP D5 Benzodiazepines for ≥4 weeks 115 (4.9) 45 (39.1) 70 (60.9)
START
START E3 Vitamin D supplement in patients with known osteoporosis and with previous fragility fracture 
or BMD T scores >−2.0 in multiple sites, or both 96 (4.1) 22 (22.9) 74 (77.1)
START H2 Laxatives in patients receiving opioids regularly 82 (3.5) 12 (14.6) 70 (85.4)
START A6 Angiotensin converting enzyme inhibitor with systolic heart failure or documented coronary 
artery disease, or both 80 (3.4) 19 (23.8) 61 (76.3)
START E5 Vitamin D supplement in older people who are housebound, experiencing falls, or with 
osteopenia (BMD T score >−1.0 but <−2.5 in multiple sites) 80 (3.4) 31 (38.8) 49 (61.3)
START E2 Bisphosphonates and vitamin D and calcium in patients taking long term systemic 
corticosteroid 74 (3.2) 21 (28.4) 53 (71.6)
START E4 Bone antiresorptive or anabolic treatment‡ in patients with documented osteoporosis, where 
no drug or clinical status contraindication exists (BMD T scores <−2.5 in multiple sites) or 
history of fragility fracture, or both
71 (3.0) 9 (12.7) 62 (87.3)
START A5 Statin treatment with a documented history of coronary, cerebral, or peripheral vascular 
disease, unless the patient’s status is end of life or age is >85 years 62 (2.7) 14 (22.6) 48 (77.4)
BMD=bone mineral density.
*START I1 and I2 criteria and some STRIPA (systematic tool to reduce inappropriate prescribing facilitated by web based STRIP assistant) generated signals that could not be interpreted as 
implemented recommendations were omitted from analysis.
†10 most common identified drug classes with no evidence based indication, in descending order of frequency: antacids, mineral supplements, psychoanaleptics, lipid modifying agents, 
psychotropics, antithrombotics, vitamin, analgesics (including opioids), laxatives, and drugs for obstructive airway diseases.
‡For example, bisphosphonate, strontium ranelate, teriparatide, denosumab.
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instead of cluster level randomisation. Another cluster 
randomised controlled trial of 3904 older adults 
with polypharmacy in general practices compared an 
electronic decision support tool for comprehensive 
drug review designed to deprescribe inappropriate 
drugs versus standard care.55 After 24 months, no 
between group difference was found for the composite 
endpoint of unplanned hospital admissions or 
death, although the per protocol analysis favoured 
the intervention (odds ratio 0.82, 95% confidence 
interval 0.68 to 0.98). Patients, doctors, and research 
staff were not, however, blinded, and outcomes were 
not independently adjudicated. In contrast with 
these two randomised controlled trials, in our study 
Table 4 | Clinical outcomes
Outcomes
No (%) of events
Hazard ratio (95% CI) P valueControl (n=1045) Intervention (n=963)
First drug related hospital admission 234 (22.4) 211 (21.9) 0.95 (0.77 to 1.17) 0.62
Death 203 (19.4) 172 (17.9) 0.90 (0.71 to 1.13) 0.37
Death from cancer 55 (5.3) 43 (4.5) 0.76 (0.47 to 1.23) 0.27
First hospital admission 516 (49.4) 447 (46.4) 0.87 (0.75 to 1.02) 0.08
First fall 263 (25.2) 237 (24.6) 0.96 (0.79 to 1.15) 0.64
First preventable drug related hospital admission* 100 (9.6) 84 (8.7) 0.89 (0.63 to 1.25) 0.49
First drug related hospital admission in patients with ≥1 STOPP recommendation 
implemented after two months* 156/875 (17.8) 64/398 (16.1) 0.88 (0.65 to 1.19) 0.41
In-hospital death within 2 months 54 (5.2) 41 (4.3) 0.81 (0.51 to 1.29)† 0.38
Hazard ratios and odds ratios <1 indicate fewer events in intervention group.
STOPP=screening tool of older person’s prescriptions.
*Post hoc analysis. Preventable episodes are those potentially related to drug overuse, underuse, or misuse.
†Odds ratio (95% confidence interval).
Table 5 | Drug related and patient reported outcomes by follow-up
Outcome by follow-up (month)
Control Intervention
Odds ratios†/adjusted 
difference‡ (95% CI) P valueNo*
No (%) of events/
Mean (SD) No*
No (%) of events/
Mean (SD)
Drug related outcomes
Clinically significant drug-drug interaction:
 2 893 521 (58.3) 832 462 (55.5) 0.87 (0.67 to 1.14) 0.31
Drug misuse§:
 2 893 378 (42.3) 832 355 (42.7) 0.99 (0.81 to 1.20) 0.92
Drug overuse§:
 2 893 376 (42.1) 832 348 (41.8) 0.99 (0.82 to 1.20) 0.91
Drug underuse§:
 2 893 638 (71.4) 832 583 (70.1) 0.91 (0.70 to 1.17) 0.45
Mean (SD) No of long term drugs¶:
 2 893 11.0 (4.27) 833 11.2 (4.54) −0.13 (−0.49 to 0.22) 0.47
 6 824 11.5 (4.81) 777 11.9 (5.04) −0.10 (−0.46 to 0.26) 0.60
 12 767 10.7 (4.57) 726 10.7 (4.54) −0.20 (−0.56 to 0.17) 0.29
Patient reported outcomes
Mean (SD) quality of life**:
 2 828 64.0 (20.1) 764 65.0 (19.4) 0.63 (−1.24 to 2.50) 0.51
 6 763 65.6 (18.8) 727 67.1 (17.0) 1.34 (−0.58 to 3.25) 0.17
 12 703 65.1 (19.1) 657 67.1 (17.8) 2.29 (0.31 to 4.26) 0.02
Mean (SD) pain/discomfort score††:
 2 850 1.16 (1.20) 787 1.09 (1.12) −0.04 (−0.16 to 0.07) 0.43
 6 777 1.17 (1.18) 741 1.08 (1.16) −0.07 (−0.19 to 0.04) 0.20
 12 722 1.15 (1.20) 673 1.02 (1.11) −0.11 (−0.23 to 0.01) 0.06
Mean (SD) activities of daily living‡‡:
 2 833 86.0 (21.4) 780 87.8 (19.7) 0.53 (−1.71 to 2.78) 0.64
 6 767 87.7 (19.2) 735 88.6 (19.1) 0.49 (−1.78 to 2.76) 0.67
 12 713 86.9 (20.3) 665 89.0 (18.4) 1.60 (−0.70 to 3.89) 0.17
Mean (SD) drug compliance§§:
 2 793 6.52 (0.834) 725 6.55 (0.819) 0.02 (−0.06 to 0.10) 0.68
 12 707 6.57 (0.815) 666 6.60 (0.759) 0.03 (−0.05 to 0.12) 0.46
Odds ratios relate to numbers (percentages) and adjusted differences to means (standard deviations).
*Numbers of participants differ as they were based on available data at months 2, 6, and 12; non-available data at 12 months were mainly due to death.
†Odds ratios <1 indicate fewer events in intervention group.
‡Adjusted for baseline value of outcome. Positive values indicate higher values in intervention group.
§Drugs with an indication, but error in prescribing, dispensing, administering, or monitoring. See supplementary appendix for definitions of clinically 
significant drug-drug interactions, drug overuse, and drug underuse.
¶Drug use for >30 days.
**Measured by visual analogue scale, using the second part of the European quality of life-5 dimensions questionnaire (EQ-VAS). Values range from 0 to 
100. Higher values indicate higher quality of life.
††Measured using five dimensions version of EQ-5D. Values range from 0 to 4. Higher values indicate higher level of pain or discomfort.
‡‡Measured using Barthel index. Values range from 0 to 100. Higher values indicate higher functional independence.
§§Measured using medication adherence questionnaire (MMAS-8).35-37 Values range from 0 to 8. Higher scores indicate higher levels of adherence.
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we combined software based pharmacotherapy 
optimisation with direct contact between research 
doctors or pharmacists and hospital doctors. This 
could have contributed to greater implementation 
of recommendations compared with SENATOR and 
allowed the consideration of individual patient needs 
and preferences.
Potential explanations for lack of effect on drug 
related hospital admission
Although pharmacotherapy optimisation reduced 
potentially inappropriate prescribing and led to no 
detriment to patient outcomes, there are several 
possible explanations for the lack of effect on drug 
related hospital admissions in our study. Firstly, 
the impact of a single time point pharmacotherapy 
optimisation might not persist over a one year follow-
up, during which multiple contacts with doctors 
might occur. Although we provided evidence based 
recommendations on inappropriate prescribing to 
patients’ GPs, including reasons for stopping or 
starting drugs, the contacts with other doctors (eg, 
specialists) over one year might have resulted in new 
potentially inappropriate drugs or discontinuation 
of appropriate drugs, which could have negated an 
intervention effect. Nevertheless, our point estimates 
are reassuring for a lack of detrimental effect on patient 
outcomes from primarily stopping inappropriate drugs 
and showed a pattern favouring the intervention 
that suggests the effect was as intended, albeit weak. 
Secondly, the high mortality rate of the population, 
approaching 20% at 12 months, could have diluted 
benefits from pharmacotherapy optimisation. Thirdly, 
implementation of recommendations (ie, drug 
changes recommended by STRIP) at two months was 
suboptimal, although implementation of complex 
interventions is often lower in multicentre trials (about 
15% to 42%)19  55 compared with some single centre 
trials (93%).27 The moderate implementation level 
in our study was probably multifactorial. Multiple 
prescribers’ barriers to minimising inappropriate 
prescribing have been identified.56 Our intervention 
could address some of these barriers among attending 
hospital doctors and GPs; the intervention improved 
prescriber awareness by providing evidence based 
recommendations, filled doctors’ knowledge gaps, and 
provided the resources required for pharmacotherapy 
optimisation. The intervention might, however, have 
been less successful in addressing these barriers 
among GPs who received a written report of the 
recommendations but had no direct contact with 
the intervention team, and who might not have 
implemented recommendations or reverted drug 
changes. In a recent randomised controlled trial 
involving 1499 Danish participants with polypharmacy 
admitted to hospital, the intervention incorporated 
close contact with the patient and an outpatient 
follow-up setting with motivational patient interviews 
and follow-up phone calls with outpatient providers. 
A reduced all cause hospital readmission rate (hazard 
ratio 0.75, 95% confidence interval 0.62 to 0.90) within 
180 days was observed in the extended intervention 
group compared with usual care group.57 Drug related 
hospital admissions were not, however, significantly 
reduced (0.80, 0.59 to 1.08), although this study 
was not powered to detect an effect on drug related 
hospital admissions. This study was not multinational 
and was at risk of contamination bias owing to lack of 
cluster level randomisation.30 Our study implemented 
direct interaction of doctors and pharmacists with the 
attending hospital doctors and patients with shared 
decision making. However, several recommendations 
could not be implemented during the index hospital 
admission, as some participants wanted to discuss 
them with their GPs at a future appointment, when 
additional barriers to implementation might exist. 
For example, the priority might have switched to 
issues other than inappropriate prescribing (eg, a new 
health problem or worsening of a chronic condition). 
Furthermore, similar to previous studies,58  59 the 
implementation rate of START recommendations 
that are known to reduce drug related hospital 
admissions was low, such as angiotensin converting 
enzyme inhibitors for systolic heart failure or statins 
for secondary cardiovascular prevention; this was 
possibly related to the already high drug burden in this 
population with polypharmacy (table 3). Finally, some 
frequent STRIP recommendations included common 
drugs that are unlikely to contribute relevantly to drug 
related hospital admissions, such as regular use of 
laxatives for patients taking opioids (table 3).
Implications for future research
Future pharmacotherapy optimisation trials will 
need to enforce prescribing advice implementation 
with greater involvement of the outpatient setting 
and to address more effectively doctors’ and patients’ 
perceived barriers to pharmacotherapy optimisation. 
In addition, future trials might benefit from focusing 
on specific drug classes (eg, benzodiazepines) to 
develop specific interventions combining explicit 
and implicit approaches with individual and patient 
centred decisions, accounting for barriers or enablers 
that might differ between drug classes,60 or prioritising 
medications that are more likely to be associated 
with drug related hospital admissions. Finally, future 
research needs to explore when, where, and with whom 
conversations about optimisation of pharmacotherapy 
should be taking place to best engage patients. 
Future trials should also assess implementation of 
pharmacotherapy optimisation in outpatient settings, 
such as by GPs or in pharmacies.
Strengths and limitations of this study
Our study has several strengths. Firstly, we enrolled 
people with multimorbidity with minimal exclusion 
criteria, heightening the generalisability of the results. 
Secondly, few patients were lost to follow-up, and 
death was the main reason for study discontinuation. 
Thirdly, our study design addressed many of the 
limitations of previous trials: the cluster randomisation 
design limited allocation contamination, blinding was 
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maximised, hospital admissions were adjudicated by a 
blinded adjudication committee, and statistical power 
was sufficient, with an adequate length of follow-up 
for clinical outcomes.
Our study also has some limitations. Although 
complete blinding was not possible, we sought to 
maximise blinding and to lower the risk of related bias, 
in contrast with previous trials,7 by recruiting staff 
and adjudicators or outcome assessors who were fully 
blinded; patients were partially blinded and received a 
sham intervention in the control group. In addition, the 
risk of death from cancer was included as a negative 
control outcome and did not point to strong selection 
bias. Cluster randomisation was at the doctor and not 
hospital level, and the potential for contamination 
in control clusters cannot be completely ruled out. 
However, doctors were independent in the treatment 
decisions on their units and were instructed to keep 
trial arm allocations confidential by not to sharing 
information with their doctor or pharmacist colleagues. 
STRIP was not applied in the control group and 
whether drug changes in the control group met STOPP/
START criteria was not assessed. Therefore we cannot 
rule out the possibility that some drug changes in the 
control group could have been made that were similar 
to the intervention recommendations, which might 
have led to results closer towards no between group 
difference. As we did not assess frailty at baseline, 
we cannot determine whether the intervention effect 
depended on frailty status. Relying on retrospective 
chart review for identifying drug related hospital 
admissions is the gold standard38 but depends on 
the quality of documentation in the medical record, 
particularly for assessment of potential underuse—
for example, adherence and patient preferences are 
often not documented in the medical charts. Finally, it 
could be argued that the lower limit of the confidence 
interval does not exclude the effect observed in a 
previous trial with a different follow-up period.57 The 
lower limit was, however, close to this effect, which 
still makes it unlikely that any replication of OPERAM 
would find such an effect. Moreover, the rate of the 
primary outcome in the control group was even higher 
than expected in the original sample size calculation, 
resulting in a sufficiently powered trial for the targeted 
effect.
Conclusion
In this cluster randomised controlled trial of older 
people with multimorbidity and polypharmacy 
admitted to hospital, a mean of 2.75 STOPP/START 
recommendations for each participant were provided 
in the intervention group, and 62% of participants 
had one or more recommendation implemented at 
two months, mostly discontinuation of inappropriate 
prescribing. Drug related hospital admissions were 
not significantly reduced in the intervention group 
compared with control group, despite providing 
evidence based recommendations to doctors and 
patients. However, the intervention caused no 
detriment to patient outcomes.
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